Citicoline
Sold for focus and memory. In the only randomised trial in ADHD it did no better than a dummy pill.
At a glance
| Our verdict | Did no better than placebo in the one randomised ADHD trial; $25–40 a month for an effect no one has shown. |
| Sold for | Focus, memory and ADHD (claimed) |
| How sure the evidence is | Very low |
| Cost a month | About $25 to $40 (estimated) |
Written for adults in Canada. It explains the evidence; it is not advice for you personally. Last reviewed 20 October 2026.
Supplement Check
Is it right for you?
If attention is the problem, the answer is rarely a capsule. Your check looks at sleep, activity, your questionnaire scores and the medicines you take, and tells you what is worth doing. Our Supplement Check looks at:
- Pregnancy and breastfeeding (no data)
- Anyone on levodopa, unless their doctor agrees
- Every medicine you take
Coming soon. The Supplement Check and the Online Health Assessment open once our safety testing is complete.
$59 when it opens, paid once. Adults 18 and over, anywhere in Canada. While the service is new, Dr. French reads every report himself, and your report arrives within 3 working days. More about the Supplement Check
What it is
Citicoline (CDP-choline) supplies choline and cytidine, which the body turns into uridine. It is a prescription medicine for stroke recovery in some countries and is sold here for focus and memory. Cognizin is the ingredient used in the trials.
How it acts
Its parts are used to make acetylcholine, a nerve messenger, and phosphatidylcholine, a building block of cell membranes, and are thought to help membrane repair. That is mechanism, not proof that it helps attention.
What it is used for, and what the evidence says
| Use | What the trials found | How sure we are |
|---|---|---|
| Children with ADHD | In a small randomised crossover pilot trial in children aged 7 to 12, citicoline did no better than placebo. [1] | Very low |
| Healthy teenage boys | Over 28 days, 250 to 500 mg improved attention and motor-speed test scores. The trial used the makers' ingredient and had makers among its authors. [2] | Very low |
| Adults with ADHD | No trial found. | No evidence (no trial) |
| Older adults with long-standing brain disease | A Cochrane review found some benefit on memory and behaviour in older people with chronic brain disorders. [3] That is a different group from healthy adults seeking focus. | Not graded here |
How sure we are: High means further research is very unlikely to change the answer; Moderate, it might; Low, it may well change; Very low, we are very unsure. These follow the GRADE method that guideline panels use.
Benefits
- None established in ADHD.
- Better attention test scores in one makers' trial in healthy teenage boys. [2]
Risks and side effects
- Common: headache, trouble sleeping, stomach upset.
Interactions with medicines
Our review found no report that it speeds up or blocks the liver enzymes that clear medicines; that question has not been studied for it.
| Medicine | What can happen | What to do |
|---|---|---|
| Levodopa (for Parkinson disease) | Citicoline may increase its effect | Do not take without your doctor |
| Anticholinergic medicines | Opposite effects on the same nerve messenger | Do not take |
Who should not take it
- Pregnancy and breastfeeding (no data).
- Anyone on levodopa, unless their doctor agrees.
- Under 18: outside the Supplement Check.
Dose and timing
We do not recommend a dose. For reference, trials used 250 to 500 mg a day.
What we know about Canadians
Canada has no measured national figure for ADHD (attention deficit hyperactivity disorder) in adults. Worldwide, about 2.6% of adults have ADHD that began in childhood and 6.8% have the symptoms. [4] Diagnosis and treatment in adults have risen sharply: in Ontario, new stimulant prescriptions rose 157% from 2015 to 2023, with the steepest rises in women aged 25 to 44 (up 421%) and 18 to 24 (up 369%). [5] In British Columbia, new adult diagnoses went from about 9 to 35 per 100,000 a month between before and after the pandemic. [6]
Most at risk of being newly diagnosed or treated: women aged 18 to 44. With so many more adults on stimulant medicines, what is taken alongside them matters more.
No Canadian data on citicoline use in our review.
How sure are we: low. Low for how many Canadian adults have ADHD (a global estimate); high for the rise in prescribing (whole-population Ontario and British Columbia data).
An honest comparison: adult ADHD symptoms
Effect sizes are put on one common scale so that different symptom questionnaires can be compared: the bigger the number, the more symptoms fell compared with a dummy pill (placebo). The medicine figures come from blinded trials in adults, rated by clinicians at about 12 weeks; the self-rated figures are closer to what you would notice yourself.
| Option | Effect | How sure we are | Cost a month (CAD) |
|---|---|---|---|
| Citicoline 250 to 500 mg | No better than placebo in the one randomised trial in children with ADHD [1]; no adult trial | Very low | $25 to $40 (estimated) |
| Aerobic exercise, 20 to 45 minutes most days | Core symptoms improved a small amount after a single session (effect size 0.23); results of longer programmes were mixed [7] | Low | $0 to $60 (gym) |
| Lisdexamfetamine and other amphetamines | Clinician-rated effect size 0.79, the largest of any treatment [8]; self-rated 0.39 (stimulants as a group) [9] | Moderate to High | $90 to $150 (estimated; generic lower) |
| Methylphenidate, long-acting | Clinician-rated effect size 0.49 [8] | Moderate to High | $45 to $75 (estimated) |
| Atomoxetine (non-stimulant) | Clinician-rated effect size 0.45 [8]; self-rated 0.38 [9] | Moderate | $45 to $60 (estimated) |
Why we don't recommend it
We do not sell citicoline and our check does not recommend it for focus or ADHD.
Already taking it? It is unlikely to harm you, but there is no good reason to keep paying for it. If a questionnaire suggests ADHD, that is a screen, not a diagnosis: it needs a formal assessment. If ADHD is confirmed, the prescription medicines reduce symptoms two to four times more than any supplement.
In the one randomised trial in children with ADHD, citicoline did no better than placebo; [1] the positive attention study in teenagers was run with the makers. [2] It costs $25 to $40 a month for an effect no one has shown. We would rather you spend that on exercise and getting a proper assessment if attention is a concern.
Supplement Check
Before you buy it, get it checked
If attention is the problem, the answer is rarely a capsule. Your check looks at sleep, activity, your questionnaire scores and the medicines you take, and tells you what is worth doing. Our Supplement Check looks at:
- Pregnancy and breastfeeding (no data)
- Anyone on levodopa, unless their doctor agrees
- Every medicine you take
Coming soon. The Supplement Check and the Online Health Assessment open once our safety testing is complete.
$59 when it opens, paid once. Adults 18 and over, anywhere in Canada. While the service is new, Dr. French reads every report himself, and your report arrives within 3 working days. More about the Supplement Check
Disclosure of financial interest
White Pine Medical earns money from products bought through our Fullscript dispensary. Dr. French's Code of Ethics requires him to tell you this. You do not have to buy anything from us: every product is named by its ingredient and dose so you can buy it at any pharmacy, and the advice is the same wherever you buy it, or if you buy nothing.
References
- Hübner IB, Scheibe DB, Marchezan J, Bücker J. Use of citicoline in attention-deficit/hyperactivity disorder: a pilot study. Clin Neuropharmacol. 2024;47(5):146-9. PMID 38976279.
- McGlade E, Agoston AM, DiMuzio J, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 2019;23(2):121-34. PMID 26179181.
- Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269. PMID 15846601.
- Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I, et al. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health. 2021;11:04009. PMID 33692893.
- Myran DT, MacDonald-Spracklin R, Busa G, Talarico R, Finkelstein Y. Population-level trends in attention-deficit/hyperactivity disorder medication prescribing. JAMA Netw Open. 2025;8(12):e2548532. PMID 41379449.
- Hu K, Desai R, Au S, Zhao B, Barbic S, Marchand K, et al. Trends of incident adult attention-deficit/hyperactivity disorder diagnoses before, during and after the pandemic provincial state of emergency in British Columbia (2013-2023): a population-based study. Lancet Reg Health Am. 2025;51:101223. PMID 41282502.
- Xu S, Zhao C, Hu L. The effects of acute and chronic exercise on executive functions and core symptoms in adults with ADHD: a systematic review and meta-analysis. Psychol Sport Exerc. 2026;84:103088. PMID 41638541.
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-38. PMID 30097390.
- Ostinelli EG, Schulze M, Zangani C, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry. 2025;12(1):32-43. PMID 39701638.
Costs marked as estimates are typical Canadian retail or pharmacy prices, before any drug plan. Certainty grades are ours unless the review gave its own.